UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2018
ENOCHIAN BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-54478 | 45-2559340 | ||
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
| of incorporation) | Identification No.) |
|
Century City Medical Plaza 2080 Century City East Suite 906 Los Angeles, CA 90067 (Address of principal executive offices) |
+1(510) 203-4857
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| 1 |
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On October 30, 2018, the Board of Directors (the “Board”) of Enochian Biosciences, Inc., a Delaware corporation (the “Company”) increased the size of the Board from 6 to 7 directors and appointed Luc Debruyne as a director, effective immediately.
Mr. Debruyne will receive $60,000 in cash compensation and $75,000 in stock options per year for his service as a director.
Other than the foregoing, there are no arrangements or understandings between Mr. Debruyne and any person (including the Company) pursuant to which Mr. Debruyne was appointed to serve as a director, and there are no actual or proposed transactions between Mr. Debruyne or any of his related persons and the Company that would require disclosure under Item 404(a) of Regulation S-K (17 CFR 229.404(a)) in connection with his appointment as a director.
Mr. Debruyne does not have any family relationship with any director, executive officer, or person nominated or chosen to become a director or executive officer of the Company.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Enochian Biosciences, Inc. | ||
|
|
By: /s/ Eric J. Leire Name: Eric J. Leire Title: Chief Executive Officer | |
| Date: November 5, 2018 | ||
| 3 |